{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:18:37Z","timestamp":1780928317390,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,8]]},"DOI":"10.7759\/cureus.110449","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:18:07Z","timestamp":1780924687000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Survival in IDH-Wild-Type Glioblastoma: Clinical and Molecular Insights From Two Exceptional Cases"],"prefix":"10.7759","author":[{"given":"Ezgi","family":"Gurlek Tumer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeyye","family":"Tuysuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efe","family":"Yetisgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yildiz","family":"Guney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012","volume":"17 Suppl 4","author":"Ostrom QT","year":"2015","unstructured":"Ostrom QT, Gittleman H, Fulop J, et al.. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015, 17 Suppl 4:iv1-iv62. 10.1093\/neuonc\/nov189","journal-title":"Neuro Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0275","article-title":"Epidemiologic and molecular prognostic review of glioblastoma","volume":"23","author":"Thakkar JP","year":"2014","unstructured":"Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, Villano JL. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014, 23:1985-96. 10.1158\/1055-9965.EPI-14-0275","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis DN","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, et al.. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016, 131:803-20. 10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.9832","article-title":"Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas","volume":"27","author":"Sanson M","year":"2009","unstructured":"Sanson M, Marie Y, Paris S, et al.. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009, 27:4150-4. 10.1200\/JCO.2009.21.9832","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis DN","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, et al.. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021, 23:1231-51. 10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2018.05.002","article-title":"Ten-year survival in glioblastoma. A systematic review","volume":"54","author":"Tykocki T","year":"2018","unstructured":"Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018, 54:7-13. 10.1016\/j.jocn.2018.05.002","journal-title":"J Clin Neurosci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now208","article-title":"An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825","volume":"19","author":"Gittleman H","year":"2017","unstructured":"Gittleman H, Lim D, Kattan MW, et al.. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro Oncol. 2017, 19:669-77. 10.1093\/neuonc\/now208","journal-title":"Neuro Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0007-3","article-title":"AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme","volume":"28","author":"Chinot OL","year":"2011","unstructured":"Chinot OL, de La Motte Rouge T, Moore N, et al.. AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther. 2011, 28:334-40. 10.1007\/s12325-011-0007-3","journal-title":"Adv Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim M","year":"2022","unstructured":"Lim M, Weller M, Idbaih A, et al.. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 2022, 24:1935-49. 10.1093\/neuonc\/noac116","journal-title":"Neuro Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad119","article-title":"Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial)","volume":"26","author":"Laprie A","year":"2024","unstructured":"Laprie A, Noel G, Chaltiel L, et al.. Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial). Neuro Oncol. 2024, 26:153-63. 10.1093\/neuonc\/noad119","journal-title":"Neuro Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5082","article-title":"Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial","volume":"4","author":"Taphoorn MJ","year":"2018","unstructured":"Taphoorn MJ, Dirven L, Kanner AA, et al.. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018, 4:495-504. 10.1001\/jamaoncol.2017.5082","journal-title":"JAMA Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.12.003","article-title":"ESTRO-ACROP guideline \"target delineation of glioblastomas\"","volume":"118","author":"Niyazi M","year":"2016","unstructured":"Niyazi M, Brada M, Chalmers AJ, et al.. ESTRO-ACROP guideline \"target delineation of glioblastomas\". Radiother Oncol. 2016, 118:35-42. 10.1016\/j.radonc.2015.12.003","journal-title":"Radiother Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00164","article-title":"NRG Oncology\/RTOG1205: a randomized Phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma","volume":"41","author":"Tsien CI","year":"2023","unstructured":"Tsien CI, Pugh SL, Dicker AP, et al.. NRG Oncology\/RTOG1205: a randomized Phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma. J Clin Oncol. 2023, 41:1285-95. 10.1200\/JCO.22.00164","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910373","article-title":"Prognostic and predictive biomarkers in gliomas","volume":"22","author":"\u015aledzi\u0144ska P","year":"2021","unstructured":"\u015aledzi\u0144ska P, Bebyn MG, Furtak J, Kowalewski J, Lewandowska MA. Prognostic and predictive biomarkers in gliomas. Int J Mol Sci. 2021, 22:10373. 10.3390\/ijms221910373","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.06.012","article-title":"Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma","volume":"81","author":"Li J","year":"2011","unstructured":"Li J, Wang M, Won M, Shaw EG, Coughlin C, Curran WJ Jr, Mehta MP. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys. 2011, 81:623-30. 10.1016\/j.ijrobp.2010.06.012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33378","article-title":"Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: results from the multicohort phase 1 KEYNOTE-028 trial","volume":"127","author":"Reardon DA","year":"2021","unstructured":"Reardon DA, Kim TM, Frenel JS, et al.. Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: results from the multicohort phase 1 KEYNOTE-028 trial. Cancer. 2021, 127:1620-9. 10.1002\/cncr.33378","journal-title":"Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216938","article-title":"Comprehensive molecular characterization of long-term glioblastoma survivors","volume":"593","author":"Xu H","year":"2024","unstructured":"Xu H, Chen X, Sun Y, et al.. Comprehensive molecular characterization of long-term glioblastoma survivors. Cancer Lett. 2024, 593:216938. 10.1016\/j.canlet.2024.216938","journal-title":"Cancer Lett"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bas.2022.101692","article-title":"Cystic glioblastoma: a systematic review and meta-analysis of characteristics and outcomes","volume":"2","author":"Sae-Huang M","year":"2022","unstructured":"Sae-Huang M, Smith LC, Usher I, Hill CS. Cystic glioblastoma: a systematic review and meta-analysis of characteristics and outcomes. Brain Spine. 2022, 2:101692. 10.1016\/j.bas.2022.101692","journal-title":"Brain Spine"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216711","article-title":"Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: a multicentric retrospective study","volume":"588","author":"Miele E","year":"2024","unstructured":"Miele E, Anghileri E, Calatozzolo C, et al.. Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: a multicentric retrospective study. Cancer Lett. 2024, 588:216711. 10.1016\/j.canlet.2024.216711","journal-title":"Cancer Lett"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/497642-long-term-survival-in-idh-wild-type-glioblastoma-clinical-and-molecular-insights-from-two-exceptional-cases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:18:08Z","timestamp":1780924688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/497642-long-term-survival-in-idh-wild-type-glioblastoma-clinical-and-molecular-insights-from-two-exceptional-cases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.110449","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,8]]}}}